# Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact

> **NCT04665089** · NA · COMPLETED · sponsor: **Tunis University** · enrollment: 110 (actual)

## Conditions studied

- Sepsis
- Septic Shock
- Immunoinflammatory Response

## Interventions

- **DRUG:** Erythromycin

## Key facts

- **NCT ID:** NCT04665089
- **Lead sponsor:** Tunis University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-01
- **Primary completion:** 2023-01-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04665089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04665089, "Erythromycin in Septic Patients: Immunomodulatory Role and Clinical Impact". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04665089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*